These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83 related articles for article (PubMed ID: 27793157)
1. Integrating a prospective pilot trial and patient-derived xenografts to trace metabolic changes associated with acute myeloid leukemia. Carrabba MG; Tavel L; Oliveira G; Forcina A; Quilici G; Nardelli F; Tresoldi C; Ambrosi A; Ciceri F; Bernardi M; Vago L; Musco G J Hematol Oncol; 2016 Oct; 9(1):115. PubMed ID: 27793157 [TBL] [Abstract][Full Text] [Related]
2. The rarity of ALDH(+) cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patients. Hoang VT; Buss EC; Wang W; Hoffmann I; Raffel S; Zepeda-Moreno A; Baran N; Wuchter P; Eckstein V; Trumpp A; Jauch A; Ho AD; Lutz C Int J Cancer; 2015 Aug; 137(3):525-36. PubMed ID: 25545165 [TBL] [Abstract][Full Text] [Related]
3. Serum metabonomics of acute leukemia using nuclear magnetic resonance spectroscopy. Musharraf SG; Siddiqui AJ; Shamsi T; Choudhary MI; Rahman AU Sci Rep; 2016 Aug; 6():30693. PubMed ID: 27480133 [TBL] [Abstract][Full Text] [Related]
4. Differentiation and prognostic stratification of acute myeloid leukemia by serum-based spectroscopy coupling with metabolic fingerprints. Duan Z; Chen Y; Ye M; Xiao L; Chen Y; Cao Y; Peng Y; Zhang J; Zhang Y; Yang T; Liu W; Feng S; Hu J FASEB J; 2022 Jul; 36(7):e22416. PubMed ID: 35713583 [TBL] [Abstract][Full Text] [Related]
14. A comprehensive analysis of primary acute myeloid leukemia identifies biomarkers predicting susceptibility to human allogeneic Vγ9Vδ2 T cells. Gundermann S; Klinker E; Kimmel B; Flierl U; Wilhelm M; Einsele H; Kunzmann V J Immunother; 2014; 37(6):321-30. PubMed ID: 24911793 [TBL] [Abstract][Full Text] [Related]
15. Current and emerging therapies for acute myeloid leukemia. Robak T; Wierzbowska A Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045 [TBL] [Abstract][Full Text] [Related]
16. SUMOylation of sPRDM16 promotes the progression of acute myeloid leukemia. Dong S; Chen J BMC Cancer; 2015 Nov; 15():893. PubMed ID: 26559765 [TBL] [Abstract][Full Text] [Related]
17. An extensive pharmacokinetic, metabolic and toxicological review of elderly patients under intensive chemotherapy for acute myeloid leukemia. Kaur I; Constance JE; Kosak KM; Spigarelli MG; Sherwin CM Expert Opin Drug Metab Toxicol; 2015 Jan; 11(1):53-65. PubMed ID: 25488904 [TBL] [Abstract][Full Text] [Related]
18. Metabolomic profiling of drug responses in acute myeloid leukaemia cell lines. Tiziani S; Lodi A; Khanim FL; Viant MR; Bunce CM; Günther UL PLoS One; 2009; 4(1):e4251. PubMed ID: 19158949 [TBL] [Abstract][Full Text] [Related]
19. Pilot study of erlotinib in patients with acute myeloid leukemia. Sayar H; Czader M; Amin C; Cangany M; Konig H; Cripe LD Leuk Res; 2015 Feb; 39(2):170-2. PubMed ID: 25498508 [TBL] [Abstract][Full Text] [Related]